Helen Frankenthaler Foundation

IVF medication supplier

Therapeutic Area Obstetrics Gynecology Women S Health | Pharma API CDMO Database | Business leads | Prospection | PharmaCompass.com

Pipeline Prospector: Obstetrics/Gynecology/Women's Health (Preclinical, United States)

This website uses cookies. We use cookies to personalise content and ads, to provide social media features and to analyse our traffic.

Consent Selection

  • Necessary
  • Preferences
  • Statistics
  • Marketing
  • Show details
  • Allow all
  • Allow selection

Market Place Sourcing Support

  • Login
  • Find Suppliers : API/FDF
  • Services
  • Excipients
  • NEW Find Prospects
  • News
  • Blog
  • Prospector
  • RESET ALL

Database Summary

  • Companies: 14819
  • Lead Products: 30335
  • Therapeutic Areas: 29
  • Clinical Studies: 83128
  • Product Types: 31

Please log in to download data via email.

Filter Options

  • COMPANY NAME: All
  • COUNTRY HQ: All
  • LEAD PRODUCT: All
  • PRODUCT STATUS: All
  • STUDY PHASE: All
  • MOLECULE TYPE: All
  • PRODUCT TYPE: All
  • HPAPI: OEL at or below 10 µg/m³, typically after Phase 2
  • THERAPEUTIC AREA: All
  • DOSAGE FORM: All

Sample Company Addresses

  • Kalina, Santacruz East, Mumbai 400 098
  • 69 Amman 11591 Jordan
  • Av. Cafe, 277 - 7o. Andar Torre B
  • 72 Tianhe Street, Changchun High-Tech Dev. Zone, Changchun, Jilin,130012
  • Head Office Jl. Veteran No. 9 Jakarta 10110
  • 21 Chemin de la Sauvegarde 69130 Ecully
  • 1900-1 Togo, Mobara, Chiba
  • 4895 HICKMORE
  • 35 CHANNEL DRIVE
  • Via Cresole, 8
  • Hulstweg 11

Data Views

  • Company
  • Lead Product
  • Study Phase
  • Therapeutic Area
  • Companies by Lead Products
  • Lead Products by Companies
  • Study Phase by Lead Products
  • Therapeutic Area by Lead Products

Pipeline Data Table

<
CompanyLead ProductOther Lead ProductsStudy PhaseStudy StatusMedical ConditionTherapeutic AreaMolecule TypeProduct TypeDosage FormSponsorDateSource
Avidity BiosciencesATR 1072InapplicablePreclinicalActivePRKAG2 SyndromeCardiovascular DiseasesBiologicalAntibody-oligonucleotide ConjugateUndisclosedAvidity Biosciences27-Feb-26Atrium Therapeutics Launches with $270M for RNA Medicines in Rare Genetic Cardiomyopathies
PhotocureHexaminolevulinate HClInapplicablePhase IIIActiveSquamous Intraepithelial LesionsOncologyChemicalSmall Molecule (Miscellaneous)OintmentAsieris Pharmaceuticals27-Feb-26Asieris Announces EMA Acceptance of CEVIRA Marketing Application in Europe
WuXi XDCUndisclosedInapplicableDiscovery PlatformActiveAutoimmune DiseasesImmunologyBiologicalAntibody-drug ConjugateUndisclosedEarendil Labs27-Feb-26WuXi XDC Collaborates with Earendil Labs on WuXiTecan-2 Payload-Linker Platform
Novo NordiskSemaglutideInapplicableApproved FDFActiveDiabetes Mellitus, Type 2EndocrinologyChemicalPeptide, UnconjugatedInjectionAbbott Laboratories27-Feb-26Abbott Partners with Novo Nordisk for Semaglutide Deal
Avidity BiosciencesDelpacibart EtedesiranInapplicablePhase IIIActiveMuscular Dystrophy, DuchenneGenetic DiseaseBiologicalAntibody-oligonucleotide ConjugateInfusionNovartis Pharmaceuticals Corporation27-Feb-26Novartis Completes Avidity Biosciences Acquisition, Boosting Neuroscience Pipeline
IRLABIRL757InapplicablePhase IActiveApathy-associated with Parkinson DiseasePsychiatryChemicalSmall Molecule (Miscellaneous)CapsuleMcQuade Center for Strategic Research and Development26-Feb-26Irlab Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson's
Celyn TherapeuticsMaduramicinInapplicablePreclinicalActiveCarcinoma, Non-Small-Cell LungOncologyChemicalSmall Molecule (Miscellaneous)UndisclosedKairos Pharma26-Feb-26Kairos Pharma Signs Term Sheet for Acquisition of Two Oncology Assets from Celyn Therapeutics
SynthekineSTK-012PembrolizumabPhase I/ Phase IIActiveCarcinoma, Non-Small-Cell LungOncologyBiologicalProteinInjectionMerck & Co26-Feb-26Synthekine Collaborates with Merck to Evaluate STK-012 with Keytruda in Lung Cancer Trial
Quotient SciencesPalovaroteneInapplicableApproved FDFActiveMyositis OssificansMusculoskeletalChemicalSmall Molecule (Miscellaneous)CapsuleIpsen26-Feb-26Quotient Sciences Extends Partnership for Ultra-Rare Disease Treatment Manufacturing
SitryxUndisclosedInapplicablePreclinicalActiveAutoimmune DiseasesImmunologyChemicalSmall Molecule (Miscellaneous)UndisclosedBoehringer Ingelheim GmbH26-Feb-26Boehringer Ingelheim Licenses Novel Oral Therapeutics Program for Immune Diseases from Sitryx Therapeutics
AiCurisPritelivirInapplicablePhase IIIActiveHerpes SimplexInfectious DiseasesChemicalSmall Molecule (Miscellaneous)TabletAsahi Kasei Pharma26-Feb-26Asahi Kasei Acquires Aicuris for Growth in Severe Infectious Diseases
PharmAla BiotechMidomafetamineInapplicablePhase IActiveFibromyalgiaMusculoskeletalChemicalControlled SubstanceCapsuleSpaulding Rehabilitation26-Feb-26PharmAla Signs Drug Donation Agreement for MDMA Therapy Trial in Fibromyalgia
Zydus LifesciencesSemaglutideInapplicableApproved FDFActiveDiabetes Mellitus, Type 2EndocrinologyChemicalPeptide, UnconjugatedInjectionUndisclosed26-Feb-26Zydus Plans Launch of Semaglutide Generic in Reusable Pen Form
AntengeneATG-037JS207Phase IActiveNeoplasmsOncologyChemicalSmall Molecule (Miscellaneous)UndisclosedShanghai Junshi Biosciences25-Feb-26Antengene, Junshi Biosciences collaborate on ATG-037 and JS207 synergy
Shilpa BiologicalsUndisclosedInapplicableUndisclosedActiveUndisclosedUndisclosedBiologicalLarge Molecule (Miscellaneous)UndisclosedSteinCares25-Feb-26SteinCares, Shilpa Biologicals Expand Biosimilars Access in Latin America
ChemifyUndisclosedInapplicableDiscovery PlatformActiveCardiometabolic DiseasesCardiovascular DiseasesChemicalSmall Molecule (Miscellaneous)UndisclosedSanacor25-Feb-26Chemify, Sanacor Partner for Small Molecule Therapies in Cardiometabolic Diseases
AlchemedicineAK1960InapplicablePhase IActiveAutoimmune DiseasesImmunologyChemicalSmall Molecule (Miscellaneous)UndisclosedAsahi Kasei Pharma25-Feb-26Asahi Kasei Pharma Enhances Pipeline with Global License for Novel Compounds from Alchemedicine
GenEditBRZ-101InapplicableIND EnablingActiveDiabetes Mellitus, Type 1EndocrinologyBiologicalLarge Molecule (Miscellaneous)UndisclosedYuanta Investment | DSC Investment | SV investment | Kiwoom Investment | STIC Ventures | Top Harvest Capital25-Feb-26BreezeBio Raises Series B Funds for Precision Genetic Medicines Pipeline
George MedicinesTelmisartanAmlodipine | IndapamidePhase IIIActiveHypertensionCardiovascular DiseasesChemicalSmall Molecule (Miscellaneous)TabletOrient EuroPharma25-Feb-26George Medicines Expands GMRx2 Strategy with Orient EuroPharma Licensing in Southeast Asia
Basilea PharmaceuticaCeftibutenLedaborbactam EtzadroxilPhase IActiveUrinary Tract InfectionsInfectious DiseasesChemicalAntibioticCapsuleBARDA25-Feb-26Basilea gets additional USD 6M from BARDA for ceftibuten-ledaborbactam.
EthrisUndisclosedInapplicableIND EnablingActiveInfluenza PandemicInfectious DiseasesBiologicalVaccineInjectionHaDEA25-Feb-26Ethris in EUR 148M Consortium for Novel Pandemic Influenza Vaccine
35PharmaHS235InapplicablePhase IActivePulmonary Arterial HypertensionCardiovascular DiseasesBiologicalProteinInjectionGSK25-Feb-26GSK Acquires 35Pharma to Develop HS235 for Pulmonary Hypertension
VivtexUndisclosedInapplicableDiscoveryActiveObesityNutrition & Weight LossChemicalPeptide, UnconjugatedUndisclosedNovo Nordisk25-Feb-26Novo Nordisk, Vivtex Partner for Next-Gen Oral Meds in Obesity, Diabetes
Palvella TherapeuticsSirolimusInapplicablePhase IIIActiveLymphatic AbnormalitiesOncologyChemicalAntibioticGelTD Cowen | Cantor | Stifel | Mizuho | LifeSci Capital | Oppenheimer & Co | Canaccord Genuity | H.C. Wainwright & Co25-Feb-26Palvella Therapeutics Prices Upsized Public Offering
Larimar TherapeuticsNomlabofuspInapplicablePhase IActiveFriedreich AtaxiaGenetic DiseaseBiologicalProteinInjectionJ.P. Morgan | Guggenheim Securities25-Feb-26Larimar Therapeutics Plans $75M Public Offering
Merck & CoCalderasibPembrolizumab | Berahyaluronidase AlfaPhase IIINot Yet RecruitingCarcinoma, Non-Small-Cell LungOncology